NanoViricides, Inc. (NASDAQ:NNVC)

BRIEF

published on 05/29/2024 at 12:35, 1 year 8 months ago

NanoViricides Unveils Revolutionary Broad-Spectrum Antiviral Agent

NV-387 Clinical Trials Antiviral Nanomedicine Broad-spectrum
PRESS RELEASE

published on 05/29/2024 at 12:30, 1 year 8 months ago

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
NanoViricides, Inc. elaborates on its groundbreaking host-mimetic, broad-spectrum antiviral technology platform, NV-387, designed to revolutionize viral infection treatment with advanced decoy mechanisms

NV-387 NanoViricides Inc. Broad-spectrum Host-mimetic Technology Antiviral Agent
BRIEF

published on 05/23/2024 at 12:35, 1 year 8 months ago

NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.

NanoViricides NV-387 Partnership Antiviral Aagami
PRESS RELEASE

published on 05/23/2024 at 12:30, 1 year 8 months ago

NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
NanoViricides, Inc. engages Aagami, Inc. to seek licensing and partnering opportunities for its antiviral nanomedicines including key asset NV-387. Aagami to focus on India and Japan

NV-387 NanoViricides Inc. Antiviral Nanomedicines Aagami Inc. Licensing And Partnering Opportunities
BRIEF

published on 05/20/2024 at 12:35, 1 year 8 months ago

NV-387 Shows Promising Results in Treating Lethal RSV Infection in Animal Study

NanoViricides NV-387 Clinical Trials Antiviral RSV
PRESS RELEASE

published on 05/20/2024 at 12:30, 1 year 8 months ago

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
NanoViricides, Inc. announces strong antiviral activity of NV-387 against RSV, Influenza A, and Coronaviruses in lethal lung infection models, potentially offering a cure for RSV infection

NV-387 Clinical Trials NanoViricides Inc. Antiviral RSV
BRIEF

published on 05/15/2024 at 12:35, 1 year 8 months ago

NanoViricides Reports Financial Update and Advancements in Clinical Trials

NanoViricides NV-387 Financial Report Clinical Trials Antiviral Treatment
PRESS RELEASE

published on 05/15/2024 at 12:30, 1 year 8 months ago

NanoViricides Has Filed its Quarterly Report
NanoViricides, Inc. reports advancing NV-387 to Phase II Clinical Trial for RSV infection treatment. Financial status and future plans discussed

NV-387 Phase II Clinical Trial NanoViricides Inc. RSV Infection Antiviral Nanomedicines
BRIEF

published on 05/14/2024 at 12:35, 1 year 8 months ago

NanoViricides Announces Breakthrough in RSV Treatment with NV-387

NanoViricides NV-387 Pharmaceutical Innovation RSV Treatment Antiviral Research
PRESS RELEASE

published on 05/14/2024 at 12:30, 1 year 8 months ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides, Inc. announces complete survival of animals lethally infected with RSV in lungs upon NV-387 oral treatment. Promising antiviral activity shown in study

NV-387 NanoViricides Inc. Antiviral Treatment RSV Infection Lung Infection

Published on 01/30/2026 at 08:35, 19 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 54 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 6 hours 39 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 8 hours 54 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 9 hours 54 minutes ago

PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A

View all ACCESSWIRE

Published on 01/30/2026 at 08:29, 25 minutes ago

Notice of Early Redemption
Published on 01/30/2026 at 08:00, 54 minutes ago

Ørsted to present its annual report for 2025 on February 6
Published on 01/30/2026 at 08:00, 54 minutes ago

Transaction in Own Shares
Published on 01/30/2026 at 08:00, 54 minutes ago

Aquis Stock Exchange: Admission to trading
Published on 01/30/2026 at 07:29, 1 hour 25 minutes ago

Consolidated profit (excluding Russia) above 1.4 billion euros

View all EQS

Published on 01/30/2026 at 08:00, 54 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 14 hours 54 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 15 hours 9 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 15 hours 9 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 15 hours 14 minutes ago

ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

News